Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
The closing price of Organon & Co (NYSE: OGN) was $7.11 for the day, down -0.97% from the previous closing price of $7.18. In other words, the price has decreased by -$0.97 from its previous closing price. On the day, 4.32 million shares were traded. OGN stock price reached its highest trading level at $7.15 during the session, while it also had its lowest trading level at $7.02.
Ratios:
Our analysis of OGN’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.75 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 2.38. For the most recent quarter (mrq), Quick Ratio is recorded 1.20 and its Current Ratio is at 1.75. In the meantime, Its Debt-to-Equity ratio is 9.74 whereas as Long-Term Debt/Eq ratio is at 9.69.
Upgrades & Downgrades
In the most recent recommendation for this company, Barclays on December 09, 2025, initiated with a Underweight rating and assigned the stock a target price of $7.50.
On October 27, 2025, Piper Sandler Downgraded its rating to Underweight which previously was Overweight but kept the price unchanged to $5.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Nov 12 ’25 when COX CARRIE SMITH bought 65,400 shares for $7.67 per share. The transaction valued at 501,755 led to the insider holds 77,869 shares of the business.
COX CARRIE SMITH bought 12,469 shares of OGN for $100,591 on May 14 ’25. The Director now owns 12,469 shares after completing the transaction at $8.07 per share. On May 07 ’25, another insider, Falcione Aaron, who serves as the Chief Human Resources Officer of the company, bought 5,500 shares for $8.77 each. As a result, the insider paid 48,235 and bolstered with 62,974 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OGN now has a Market Capitalization of 1848478592 and an Enterprise Value of 10004478976. As of this moment, Organon’s Price-to-Earnings (P/E) ratio for their current fiscal year is 3.70, and their Forward P/E ratio for the next fiscal year is 1.80. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.29 while its Price-to-Book (P/B) ratio in mrq is 2.04. Its current Enterprise Value per Revenue stands at 1.588 whereas that against EBITDA is 5.923.
Stock Price History:
The Beta on a monthly basis for OGN is 0.54, which has changed by -0.51876676 over the last 52 weeks, in comparison to a change of 0.17823458 over the same period for the S&P500. Over the past 52 weeks, OGN has reached a high of $17.23, while it has fallen to a 52-week low of $6.18. The 50-Day Moving Average of the stock is -3.69%, while the 200-Day Moving Average is calculated to be -26.74%.
Shares Statistics:
OGN traded an average of 5.79M shares per day over the past three months and 4503770 shares per day over the past ten days. A total of 259.98M shares are outstanding, with a floating share count of 258.95M. Insiders hold about 0.40% of the company’s shares, while institutions hold 77.99% stake in the company. Shares short for OGN as of 1765756800 were 16602771 with a Short Ratio of 2.87, compared to 1763078400 on 15587869. Therefore, it implies a Short% of Shares Outstanding of 16602771 and a Short% of Float of 8.51.
Earnings Estimates
Organon & Co (OGN) is presently subject to a detailed evaluation by 5.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is $1.01, with high estimates of $1.09 and low estimates of $0.91.
Analysts are recommending an EPS of between $3.84 and $3.62 for the fiscal current year, implying an average EPS of $3.77. EPS for the following year is $3.96, with 7.0 analysts recommending between $4.11 and $3.81.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 3 analysts. It ranges from a high estimate of $1.54B to a low estimate of $1.49B. As of. The current estimate, Organon & Co’s year-ago sales were $1.59BFor the next quarter, 3 analysts are estimating revenue of $1.52B. There is a high estimate of $1.59B for the next quarter, whereas the lowest estimate is $1.44B.
A total of 5 analysts have provided revenue estimates for OGN’s current fiscal year. The highest revenue estimate was $6.25B, while the lowest revenue estimate was $6.2B, resulting in an average revenue estimate of $6.23B. In the same quarter a year ago, actual revenue was $6.4BBased on 6 analysts’ estimates, the company’s revenue will be $6.18B in the next fiscal year. The high estimate is $6.33B and the low estimate is $5.94B.
